ZA200101821B - Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection. - Google Patents

Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection.

Info

Publication number
ZA200101821B
ZA200101821B ZA200101821A ZA200101821A ZA200101821B ZA 200101821 B ZA200101821 B ZA 200101821B ZA 200101821 A ZA200101821 A ZA 200101821A ZA 200101821 A ZA200101821 A ZA 200101821A ZA 200101821 B ZA200101821 B ZA 200101821B
Authority
ZA
South Africa
Prior art keywords
indole
amides
carbonyl
infection
treatment
Prior art date
Application number
ZA200101821A
Other languages
English (en)
Inventor
Sutcliffe Joyce Anne
Treadway Judith Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200101821B publication Critical patent/ZA200101821B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200101821A 2000-03-07 2001-03-05 Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection. ZA200101821B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18760500P 2000-03-07 2000-03-07

Publications (1)

Publication Number Publication Date
ZA200101821B true ZA200101821B (en) 2002-09-05

Family

ID=22689670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200101821A ZA200101821B (en) 2000-03-07 2001-03-05 Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection.

Country Status (10)

Country Link
US (1) US6555569B2 (fr)
EP (1) EP1149580A1 (fr)
JP (1) JP2001247565A (fr)
KR (1) KR20010088417A (fr)
AU (1) AU2487101A (fr)
CA (1) CA2339676A1 (fr)
HU (1) HUP0100973A3 (fr)
IL (1) IL141767A0 (fr)
NZ (1) NZ510369A (fr)
ZA (1) ZA200101821B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
WO2004009084A1 (fr) * 2002-07-18 2004-01-29 Pfizer Products Inc. Procedes de traitement d'une infection avec des antibiotiques et des inhibiteurs de glycogene phosphorylase
GB0319690D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2006055435A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes
WO2006053274A2 (fr) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase
WO2006055462A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
WO2006055463A2 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives de 2-amino-3-tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
WO2006082400A1 (fr) * 2005-02-05 2006-08-10 Astrazeneca Ab Dérivés d’indanamide présentant une activité inhibitrice de la glycogène phosphorylase
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
JPWO2007020936A1 (ja) * 2005-08-17 2009-02-26 第一三共株式会社 抗真菌作用二環性複素環化合物
EP2096111A1 (fr) * 2006-11-20 2009-09-02 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
WO2014071198A1 (fr) * 2012-11-01 2014-05-08 The University Of Chicago Méthodes antibiotiques et compositions d'antibiotique pour des infections bactériennes
KR20190104524A (ko) * 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
CA3061238A1 (fr) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Derives d'indole utilises en tant qu'inhibiteurs de pompe d'efflux
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US11180459B2 (en) 2017-03-10 2021-11-23 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (fr) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey Inhibiteurs de pompe d'efflux bactérien
US11458121B2 (en) 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342471C (fr) * 1995-06-06 2002-10-29 Judith L. Treadway Intermediaires amines de carbonyle-methyle heterocycliques
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
US5882885A (en) 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1056729B1 (fr) * 1998-02-27 2004-12-29 Pfizer Products Inc. Derives de la n- (a cycle di ou triaza diinsature substitue) carbonyle] guanidine utilises pour le traitement de l'ischemie

Also Published As

Publication number Publication date
CA2339676A1 (fr) 2001-09-07
IL141767A0 (en) 2002-03-10
KR20010088417A (ko) 2001-09-26
EP1149580A1 (fr) 2001-10-31
HUP0100973A2 (hu) 2002-02-28
US20010046985A1 (en) 2001-11-29
HUP0100973A3 (en) 2002-12-28
AU2487101A (en) 2001-09-13
US6555569B2 (en) 2003-04-29
HU0100973D0 (en) 2001-05-28
NZ510369A (en) 2003-01-31
JP2001247565A (ja) 2001-09-11

Similar Documents

Publication Publication Date Title
ZA200101821B (en) Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection.
MXPA03006260A (es) Derivados de amina sustituidos y metodos de uso.
GB0125222D0 (en) Composition for the treatment of microbial infections
NO20001870D0 (no) Ny fremgangsmõte for behandling
HUP0302630A3 (en) Sterilisation of pharmaceuticals
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL152553A0 (en) Compounds and methods for the treatment and prevention of bacterial infection
EG25829A (en) Novel treatment
HRP20031063A2 (en) New derivatives of oxazolidinones as antibacterial agents
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
GB0030845D0 (en) Novel treatment
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2001253568A1 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
HK1064609A1 (en) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino alkyl -acid derivatives for the treatment of pain
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
IS6626A (is) Kristallskenndur meðferðarmiðill
EP1420808A4 (fr) Traitement de la tuberculose au moyen de composes immunomodulateurs
HK1073243A1 (en) Use of N-(indolecarbonyl-) piperazine derivatives
EP1451308A4 (fr) Utilisation therapeutique de composes aziridino
GB0111745D0 (en) Sterilization of pharmaceuticals
GB0019728D0 (en) Novel treatment
AU2002333843A1 (en) Substituted n-(1,4,5,6-tetrahydrocyclopentapyrazol-3-yl) derivatives and the use of the same for the treatment of cancer